- Home
- GTEC vs SNSE Comparison
GTEC vs SNSE Comparison
Compare GTEC & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | SNSE |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | 340 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GTEC | SNSE |
|---|---|---|
| Price | $0.64 | $12.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | ★ 144.4K | 35.3K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $5.86 |
| 52 Week High | $2.26 | $36.76 |
Technical Indicators
Market Signals| Indicator | GTEC | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 36.14 |
| Support Level | $0.64 | $8.27 |
| Resistance Level | $0.73 | $34.93 |
| Average True Range (ATR) | 0.06 | 2.50 |
| MACD | 0.00 | -0.22 |
| Stochastic Oscillator | 57.45 | 20.71 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).